Shots:
- CSPC has entered a strategic collaboration & license deal with AZ to develop long-acting peptides, using CSPC’s sustained-release delivery tech platform & AI-driven peptide drug discovery platform
- As per the deal, the Group will collaborate with AZ on novel peptide discovery & long-acting delivery, while AZ will gain exclusive global rights (excl. Greater China) to the Group’s QM injectable weight management portfolio, incl. SYH2082 entering P-I, 3 preclinical assets, & 4 co-developed programs
- For AZ’s access to 8 programs & the platforms, the Group will receive $1.2B upfront, ~$3.5B in R&D milestones, ~$13.8B in sales milestones, with up to double-digit royalties on annual net sales of licensed products
Ref: CSPC | Image: CSPC & AstraZeneca | Press Release
Related News: AstraZeneca Partners with CSPC Pharmaceuticals to Identify and Develop Small Molecule Across Chronic Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
